Maintenance regimen may be effective against multiple myeloma
According to a small study by Chinese researchers, patients with Multiple Myeloma may benefit from a salvage therapy involving continuous, low-dose treatment with two very familiar chemotherapeutic drugs: cyclophosphamide (Cytoxan) and prednisone.
BLOOD CANCER SUBTYPE(S) IN QUESTION
Multiple Myeloma
COHORT
Patients: 27
Prior treatments: Patients had received between 1 and 4 previous chemotherapy regimens
RESEARCH FINDINGS
In this study, researchers wanted to evaluate the efficacy and tolerability of cyclophosphamide (50mg) and prednisone (15mg) given orally every day. Researchers followed up every two months for a median 11 months.
Results after three months:
Overall response rate: 66.7% (18 patients)
Complete response rate: 7.4% (2 patients)
No response was seen in 25.9% (7 patients) while 7.4% (2 patients) saw their disease get worse.
PUBLICATION & SOURCES
This study was published in the journal Clinical Lymphoma, Myeloma & Leukemia.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
